The US FDA has approved atrasentan, a potent and selective endothelin A receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression, with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g. Clinical evidence In clinical trials involving 270 patients receiving renin-angiotensin system inhibitor therapy, atrasentan led to a 38% reduction in UPCR, compared to just 3% in the placebo group at week 36.
Dosage and administration Available as tablet 0.75 mg orally once daily with or without food Contraindications Pregnancy Hypersensitivity Warnings and precautions Hepatotoxicity Fluid retention Decreased sperm counts Adverse reactions Peripheral edema Anemia Did you find this FDA Alert interesting? Source : FDA ##Disclaimer## The content provided on Docplexus is intended for educational purposes…
